vs
STANDARD BIOTOOLS INC.（LAB）与Quanterix Corp（QTRX）财务数据对比。点击上方公司名可切换其他公司
Quanterix Corp的季度营收约是STANDARD BIOTOOLS INC.的13.6倍（$43.9M vs $3.2M）。STANDARD BIOTOOLS INC.净利率更高（598.5% vs -52.7%，领先651.2%）。STANDARD BIOTOOLS INC.同比增速更快（262.0% vs 24.7%）。STANDARD BIOTOOLS INC.自由现金流更多（$-1.7M vs $-16.5M）。过去两年Quanterix Corp的营收复合增速更高（16.9% vs -73.4%）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
Quanterix Corp是一家生命科学企业，研发、生产和销售超高灵敏度单分子检测诊断平台、试剂及检测服务，覆盖肿瘤、神经退行性疾病、传染病等领域，为全球科研机构、生物制药企业及临床实验室提供研究、药物开发及临床诊断相关支持。
LAB vs QTRX — 直观对比
营收规模更大
QTRX
是对方的13.6倍
$3.2M
营收增速更快
LAB
高出237.3%
24.7%
净利率更高
LAB
高出651.2%
-52.7%
自由现金流更多
LAB
多$14.9M
$-16.5M
两年增速更快
QTRX
近两年复合增速
-73.4%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $3.2M | $43.9M |
| 净利润 | $19.3M | $-23.1M |
| 毛利率 | 83.5% | 45.7% |
| 营业利润率 | -578.6% | -56.4% |
| 净利率 | 598.5% | -52.7% |
| 营收同比 | 262.0% | 24.7% |
| 净利润同比 | 156.6% | -98.8% |
| 每股收益（稀释后） | $0.05 | $-0.48 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LABQTRX
| Q4 25 | $3.2M | $43.9M | ||
| Q3 25 | $19.6M | $40.2M | ||
| Q2 25 | $21.8M | $24.5M | ||
| Q1 25 | $40.8M | $30.3M | ||
| Q4 24 | $890.0K | $35.2M | ||
| Q3 24 | $22.1M | $35.8M | ||
| Q2 24 | $22.5M | $34.4M | ||
| Q1 24 | $45.5M | $32.1M |
净利润LABQTRX
| Q4 25 | $19.3M | $-23.1M | ||
| Q3 25 | $-34.7M | $-33.5M | ||
| Q2 25 | $-33.5M | $-30.0M | ||
| Q1 25 | $-26.0M | $-20.5M | ||
| Q4 24 | $-34.1M | $-11.6M | ||
| Q3 24 | $-26.9M | $-8.4M | ||
| Q2 24 | $-45.7M | $-7.4M | ||
| Q1 24 | $-32.2M | $-11.2M |
毛利率LABQTRX
| Q4 25 | 83.5% | 45.7% | ||
| Q3 25 | 48.5% | 42.8% | ||
| Q2 25 | 48.8% | 46.2% | ||
| Q1 25 | 48.4% | 54.1% | ||
| Q4 24 | -202.8% | 63.0% | ||
| Q3 24 | 54.9% | 56.3% | ||
| Q2 24 | 46.1% | 64.7% | ||
| Q1 24 | 53.1% | 57.8% |
营业利润率LABQTRX
| Q4 25 | -578.6% | -56.4% | ||
| Q3 25 | -168.5% | -92.8% | ||
| Q2 25 | -118.1% | -151.6% | ||
| Q1 25 | -80.8% | -86.9% | ||
| Q4 24 | -1162.1% | -42.0% | ||
| Q3 24 | -120.9% | -32.8% | ||
| Q2 24 | -134.5% | -31.8% | ||
| Q1 24 | -132.2% | -47.3% |
净利率LABQTRX
| Q4 25 | 598.5% | -52.7% | ||
| Q3 25 | -177.4% | -83.3% | ||
| Q2 25 | -153.7% | -122.6% | ||
| Q1 25 | -63.8% | -67.6% | ||
| Q4 24 | -3828.3% | -33.1% | ||
| Q3 24 | -122.0% | -23.3% | ||
| Q2 24 | -203.3% | -21.5% | ||
| Q1 24 | -70.6% | -34.8% |
每股收益（稀释后）LABQTRX
| Q4 25 | $0.05 | $-0.48 | ||
| Q3 25 | $-0.09 | $-0.73 | ||
| Q2 25 | $-0.09 | $-0.77 | ||
| Q1 25 | $-0.07 | $-0.53 | ||
| Q4 24 | $-0.06 | $-0.30 | ||
| Q3 24 | $-0.07 | $-0.22 | ||
| Q2 24 | $-0.12 | $-0.19 | ||
| Q1 24 | $-0.27 | $-0.29 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $120.9M | $29.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $424.3M | $295.7M |
| 总资产 | $567.8M | $418.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LABQTRX
| Q4 25 | $120.9M | $29.8M | ||
| Q3 25 | $129.4M | $38.3M | ||
| Q2 25 | $158.6M | $132.9M | ||
| Q1 25 | $150.9M | $76.5M | ||
| Q4 24 | $166.7M | $56.7M | ||
| Q3 24 | $210.6M | $29.3M | ||
| Q2 24 | $269.8M | $47.0M | ||
| Q1 24 | $287.1M | $45.3M |
总债务LABQTRX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $299.0K | — | ||
| Q3 24 | $55.2M | — | ||
| Q2 24 | $55.1M | — | ||
| Q1 24 | $55.0M | — |
股东权益LABQTRX
| Q4 25 | $424.3M | $295.7M | ||
| Q3 25 | $399.7M | $314.5M | ||
| Q2 25 | $424.5M | $292.5M | ||
| Q1 25 | $454.6M | $316.4M | ||
| Q4 24 | $471.7M | $330.0M | ||
| Q3 24 | $489.3M | $338.9M | ||
| Q2 24 | $510.3M | $340.8M | ||
| Q1 24 | $577.3M | $343.4M |
总资产LABQTRX
| Q4 25 | $567.8M | $418.8M | ||
| Q3 25 | $539.6M | $444.1M | ||
| Q2 25 | $557.0M | $375.6M | ||
| Q1 25 | $579.6M | $396.5M | ||
| Q4 24 | $612.3M | $406.5M | ||
| Q3 24 | $681.5M | $411.0M | ||
| Q2 24 | $708.7M | $415.9M | ||
| Q1 24 | $777.7M | $414.2M |
负债/权益比LABQTRX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.11× | — | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | 0.10× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.2M | $-16.4M |
| 自由现金流经营现金流 - 资本支出 | $-1.7M | $-16.5M |
| 自由现金流率自由现金流/营收 | -51.7% | -37.7% |
| 资本支出强度资本支出/营收 | 14.8% | 0.2% |
| 现金转化率经营现金流/净利润 | -0.06× | — |
| 过去12个月自由现金流最近4个季度 | $-82.6M | $-80.0M |
8季度趋势，按日历期对齐
经营现金流LABQTRX
| Q4 25 | $-1.2M | $-16.4M | ||
| Q3 25 | $-22.2M | $-41.2M | ||
| Q2 25 | $-20.7M | $-5.7M | ||
| Q1 25 | $-30.3M | $-13.9M | ||
| Q4 24 | $-14.1M | $-4.3M | ||
| Q3 24 | $-27.9M | $-5.7M | ||
| Q2 24 | $-39.0M | $-5.0M | ||
| Q1 24 | $-62.5M | $-20.2M |
自由现金流LABQTRX
| Q4 25 | $-1.7M | $-16.5M | ||
| Q3 25 | $-23.1M | $-41.9M | ||
| Q2 25 | $-22.6M | $-6.4M | ||
| Q1 25 | $-35.3M | $-15.1M | ||
| Q4 24 | $-17.4M | $-4.7M | ||
| Q3 24 | $-30.1M | $-6.6M | ||
| Q2 24 | $-41.0M | $-6.5M | ||
| Q1 24 | $-63.3M | $-20.7M |
自由现金流率LABQTRX
| Q4 25 | -51.7% | -37.7% | ||
| Q3 25 | -118.1% | -104.2% | ||
| Q2 25 | -103.6% | -26.3% | ||
| Q1 25 | -86.6% | -49.9% | ||
| Q4 24 | -1959.7% | -13.4% | ||
| Q3 24 | -136.4% | -18.4% | ||
| Q2 24 | -182.2% | -19.1% | ||
| Q1 24 | -138.9% | -64.5% |
资本支出强度LABQTRX
| Q4 25 | 14.8% | 0.2% | ||
| Q3 25 | 4.5% | 1.7% | ||
| Q2 25 | 8.7% | 3.2% | ||
| Q1 25 | 12.4% | 4.1% | ||
| Q4 24 | 380.0% | 1.2% | ||
| Q3 24 | 10.2% | 2.4% | ||
| Q2 24 | 8.6% | 4.7% | ||
| Q1 24 | 1.7% | 1.6% |
现金转化率LABQTRX
| Q4 25 | -0.06× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
暂无分部数据
QTRX
| Products | $29.2M | 67% |
| Consumable And Other Products | $12.7M | 29% |
| Service Type Warranties | $1.7M | 4% |
